Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Equity: 2022-2025

Historic Return on Equity for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -1.79%.

  • Prime Medicine's Return on Equity fell 66.00% to -1.79% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.79%, marking a year-over-year decrease of 66.00%. This contributed to the annual value of -1.37% for FY2024, which is 49.00% down from last year.
  • As of Q3 2025, Prime Medicine's Return on Equity stood at -1.79%, which was up 24.53% from -2.38% recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Return on Equity ranged from a high of 0.73% in Q2 2022 and a low of -2.61% during Q4 2022.
  • Moreover, its 3-year median value for Return on Equity was -1.14% (2024), whereas its average is -1.19%.
  • Data for Prime Medicine's Return on Equity shows a peak YoY increase of 140bps (in 2023) and a maximum YoY decrease of 149bps (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Prime Medicine's Return on Equity stood at -2.61% in 2022, then spiked by 140bps to -1.21% in 2023, then grew by 7bps to -1.14% in 2024, then crashed by 66bps to -1.79% in 2025.
  • Its Return on Equity stands at -1.79% for Q3 2025, versus -2.38% for Q2 2025 and -1.55% for Q1 2025.